| scholarly article | Q13442814 |
| review article | Q7318358 |
| P356 | DOI | 10.1177/106002809502900510 |
| P953 | full work available at URL | http://www.theannals.com/cgi/content/abstract/29/5/501 |
| http://journals.sagepub.com/doi/pdf/10.1177/106002809502900510 | ||
| P698 | PubMed publication ID | 7655135 |
| P2093 | author name string | K. A. Rodvold | |
| L. H. Danziger | |||
| D. J. Occhipinti | |||
| L. L. Schoonover | |||
| P2860 | cites work | Infections in medicine | Q27716726 |
| Effect of beta-lactamase inhibitors on the activities of various beta-lactam agents against anaerobic bacteria | Q33744290 | ||
| Beta-lactamase production in members of the family Enterobacteriaceae and resistance to beta-lactam-enzyme inhibitor combinations | Q35252346 | ||
| Comparative in vitro activities of a new quinolone, WIN 57273, and piperacillin plus tazobactam against anaerobic bacteria | Q35275754 | ||
| Comparative in vitro activities of piperacillin-tazobactam and ticarcillin-clavulanate | Q35343060 | ||
| Comparative in vitro and in vivo activities of piperacillin combined with the beta-lactamase inhibitors tazobactam, clavulanic acid, and sulbactam | Q35360429 | ||
| Pharmacokinetics and tissue penetration of tazobactam and piperacillin in patients undergoing colorectal surgery | Q35900491 | ||
| Piperacillin-tazobactam versus imipenem-cilastatin for treatment of intra-abdominal infections | Q36758337 | ||
| Effects of sodium piperacillin on platelet function in normal volunteers | Q39854806 | ||
| Comparative evaluation of a new beta-lactamase inhibitor, YTR 830, combined with different beta-lactam antibiotics against bacteria harboring known beta-lactamases | Q40283720 | ||
| Pharmacokinetics and tissue penetration of tazobactam administered alone and with piperacillin | Q40284229 | ||
| Piperacillin/tazobactam/amikacin versus piperacillin/amikacin/teicoplanin in the empirical treatment of neutropenic patients. | Q40723790 | ||
| Ceftazidime Monotherapy for Empiric Treatment of Febrile Neutropenic Patients: A Metaanalysis | Q40742943 | ||
| The chemistry, pharmacokinetics and tissue distribution of piperacillin/tazobactam | Q40852062 | ||
| The in-vitro activity of piperacillin/tazobactam, ciprofloxacin, ceftazidime and imipenem against multiple resistant gram-negative bacteria | Q44039660 | ||
| Susceptibility of anaerobes in phase 3 clinical studies of piperacillin/tazobactam. | Q54238651 | ||
| Activity of ticarcillin/clavulanate and piperacillin/tazobactam (YTR 830; CL-298,741) against clinical isolates and against mutants derepressed for class I beta-lactamase. | Q54342220 | ||
| Studies to optimize the in vitro testing of piperacillin combined with tazobactam (YTR 830). | Q54342222 | ||
| Comparative in vitro activity of piperacillin combined with the beta-lactamase inhibitor tazobactam (YTR 830). | Q54342227 | ||
| Single-dose pharmacokinetics of piperacillin and tazobactam in patients with renal disease | Q67485735 | ||
| Comparison of fixed concentration and fixed ratio options for testing susceptibility of gram-negative bacilli to piperacillin and piperacillin/tazobactam | Q67505982 | ||
| In vitro effect of YTR (tazobactam) on plasmid and chromosomally mediated beta-lactamases | Q68459304 | ||
| Inhibition of beta-lactamases by tazobactam and in-vitro antibacterial activity of tazobactam combined with piperacillin | Q68463081 | ||
| Piperacillin/tazobactam compared with ticarcillin/clavulanate in community-acquired bacterial lower respiratory tract infection | Q72574046 | ||
| Therapy of soft tissue infections with piperacillin/tazobactam | Q72956634 | ||
| Efficacy, safety and tolerance of parenteral piperacillin/tazobactam in the treatment of patients with lower respiratory tract infections | Q72956661 | ||
| P433 | issue | 5 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | piperacillin/tazobactam | Q7197337 |
| P304 | page(s) | 501-514 | |
| P577 | publication date | 1995-05-01 | |
| P1433 | published in | Annals of Pharmacotherapy | Q4767858 |
| P1476 | title | Piperacillin/Tazobactam: A New Beta-Lactam/Beta-Lactamase Inhibitor Combination | |
| P478 | volume | 29 |
| Q41189315 | A practical look at the clinical usefulness of the beta-lactam/beta-lactamase inhibitor combinations |
| Q35715650 | Carbapenem therapy is associated with improved survival compared with piperacillin-tazobactam for patients with extended-spectrum β-lactamase bacteremia |
| Q34520874 | Clinafloxacin versus piperacillin/tazobactam in the treatment of severe skin and soft-tissue infections in adults at a Veterans Affairs medical center |
| Q43544436 | Cost efficacy of tazobactam/piperacillin versus imipenem/cilastatin in the treatment of intra-abdominal infection |
| Q40546181 | Incidence of Neutropenia during Treatment of Bone-Related Infections with Piperacillin-Tazobactam |
| Q90616536 | Multicenter Evaluation of the New Etest Gradient Diffusion Method for Piperacillin-Tazobactam Susceptibility Testing of Enterobacterales, Pseudomonas aeruginosa, and Acinetobacter baumannii Complex |
| Q90364700 | Optimal Piperacillin-Tazobactam Dosing Strategies against Extended-Spectrum-β-Lactamase-Producing Enterobacteriaceae |
| Q35139002 | Pharmacokinetics and pharmacodynamics of two multiple-dose piperacillin-tazobactam regimens |
| Q39470971 | Piperacillin and tazobactam exhibit linear pharmacokinetics after multiple standard clinical doses |
| Q36625129 | Piperacillin/Tazobactam (ZOSYN) |
| Q33370885 | Piperacillin/tazobactam-induced paresthesiae |
| Q33649676 | Piperacillin/tazobactam: an updated review of its use in the treatment of bacterial infections |
| Q92707799 | Population Pharmacokinetics and Safety of Piperacillin-Tazobactam Extended Infusions in Infants and Children |
Search more.